HOME >> MEDICINE >> NEWS
UK study suggests possible link between colorectal cancer and human growth hormone therapy

Authors of an observational study in this week's issue of THE LANCET highlight a possible link between human growth hormone therapy and an increased risk of colorectal cancer. The investigators comment that further evidence is required before firm conclusions can be made, and stress that there is no evidence from their study as to whether there is an association between modern synthetic growth hormone treatment and increased cancer risk.

Human pituitary growth hormone was widely used to counteract short stature in children and young adults up to the mid 1980s; since then synthetic growth hormone has replaced human growth hormone therapy. Previous research has suggested a possible link between naturally occurring growth hormone concentrations and an increased risk of cancer; however there are no long-term follow-up data on growth-hormone-treated patients to support this association.

Anthony Swerdlow, Michael Preece, and colleagues from The Institute of Cancer Research and Institute of Child Health, UK, did a population study to investigate cancer incidence and death in 1848 people in the UK who were treated during childhood and early adulthood with human pituitary growth hormone between 1959 and 1985. The risk of cancer in the study population was compared with that in the general population.

Patients treated with human pituitary growth hormone had an almost threefold increased risk of death from cancer overall, and were at around an eleven times greater risk of dying from colorectal cancer or Hodgkin's disease. After the exclusion of patients whose reason for growth hormone treatment rendered them at a high risk of cancer, the risk of incidence of colorectal cancer was significant, as were the risks of death from colorectal cancer or Hodgkin's disease.

Anthony Swerdlow comments: "Our data do not show conclusively whether cancer incidence is increased by growth hormone treatment, but they do suggest the need for increased awareness of
'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-20-7424-4949
Lancet
25-Jul-2002


Page: 1 2

Related medicine news :

1. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
2. UMaine study looks at infants and chronic nighttime crying
3. Chronic pain treatments more effective when taken together, new study shows
4. UNC study: Most N.C. family practitioners engage in unrecognized community service
5. New study in Nature demonstrates protection against cell death during heart attack
6. UCSF study offers insight into human circadian rhythms
7. International breast cancer prevention study launches in the United States and Canada
8. UW study shows blacks and Latinos are more satisfied with physicians of the same race
9. Physicians may not be accurate in their confidence levels of their diagnoses, says Pitt study
10. Advertising by academic medical centers may risk eroding public trust, says study
11. Fat may promote inflammation, new study suggests

Post Your Comments:
(Date:12/19/2014)... The global magnetic resonance imaging ... that is saturated with numerous players developing innovative ... well as non-invasive nature, MRI systems have seen ... the healthcare market. Rapid advances in the field ... technologies have greatly expanded the potential of therapeutic ...
(Date:12/19/2014)... Hands On Mobile Spa, has announced they now ... Wheels has been transformed into a utopia for the Long ... to disappear. The Virtual Tour showcases the beauty of the ... events and more. , The Virtual Tour shows viewers each ... actually an overhauled Winnebago. Marla Kaplan-Pelle, Director states " It's ...
(Date:12/19/2014)... If you have ever been unable ... probably wished you had an arsenal of treatments to ... and other breathing disorders. Currently, the only proven methods ... but other common treatments do exist. At the ... Antonio, TX, 34 asthma educators responded to a Harmonica ...
(Date:12/19/2014)... Slone Partners , a national recruitment ... technology, and laboratory testing industries, has promoted Leslie ... The announcement comes after a year of expansion ... in Boston and several new additions to the ... client experience," said Adam Slone, Chief Executive Officer. ...
(Date:12/19/2014)... This is a professional and in-depth study on ... a focus on the Chinese market. The report provides ... manufacturers and is a valuable source of guidance and ... , Firstly, the report provides a basic overview of ... Then, the report explores the international and Chinese major ...
Breaking Medicine News(10 mins):Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 2Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 3Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 4Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 2Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 3Health News:Harmonica Techs, Inventors of the Pulmonica®, Unveil New Findings on Complementary Treatments for Asthma 2Health News:Harmonica Techs, Inventors of the Pulmonica®, Unveil New Findings on Complementary Treatments for Asthma 3Health News:Slone Partners Promotes Leslie Loveless to Chief Operating Officer 2Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 2Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 3Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 4Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 5Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 6
(Date:12/19/2014)... 18, 2014   Aratana Therapeutics, Inc . ... focused on the licensing, development and commercialization of ... results from its pivotal field study of AT-001 ... in dogs with osteoarthritis.  In the study, dogs ... that were statistically significant compared to placebo (p<0.05) ...
(Date:12/17/2014)... Revenue and earnings above the previous ... development In the past 2013/14 fiscal year (ended ... to EUR 4.287 billion (last year: EUR 4.190 billion) despite ... EUR 360 million. "Overall, 2013/14 was a successful fiscal year ... President and CEO of Carl Zeiss AG. "Thanks to our ...
(Date:12/17/2014)... , December 17, 2014 ... nothing less than a hub of information concerning the biopharmaceutical ... A further addition to the recently launched institutional ... and has now been enriched by a new chapter in ... A richly detailed and panoramic hub on the ...
Breaking Medicine Technology:Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS Asserts its Position in Difficult Environment 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3
Cached News: